ArticleScience progress
Long-term outcomes and prognostic factors of major amputation in thromboangiitis obliterans after drug therapy and endovascular procedures: A real-world cohort study.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Diabetic Peripheral Arterial Disease Versus Thromboangiitis Obliterans: A Multidimensional Comparison of Clinical Phenotype, Biomarkers, and Outcomes.Diagnostics (Basel, Switzerland) · 2026Article
- Clinical value of targeted arterial infusion of ginkgo biloba extract combined with urokinase in thromboangiitis obliterans.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesData regarding the long-term outcomes of patients with thromboangiitis obliterans (TAO) after drug therapy (DT) alone and endovascular procedure (EP)+ drug therapy (DT) are limited. In this study, we compared the long-term outcomes and prognostic factors of major amputation in TAO patients treated with DT alone and those treated with EP+ DT.
methodsConsecutive patients with TAO treated at Ganzhou People's Hospital between 2012 and 2022 were included in this real-world study. All patients were administered DT. Some patients were treated with EP in addition to DT. The patients were classified into two groups: the DT group and the EP+ DT group. Long-term follow-up was sustained for all patients after treatment, and limb events were documented throughout the follow-up period. Cox regression analyses were used to analyze the factors associated with major amputation of the TAO.
resultsA total of 150 TAO patients with 175 lower limb lesions were included in the study and the number of patients in DT group and EP+ DT group was 81 and 69, respectively. The technical success rate in the EP group was 82.6%. The major amputation was performed in 19 and 21 patients in the respective groups, accounting for 26.7% of the total patients. The Kaplan-Meier curves for major amputation did not significantly differ between the two groups. Cox regression analysis revealed that disease duration (hazard ratio (HR), 0.865; 95% confidence interval (CI) [0.783-0.979],
conclusionIn terms of long-term outcomes, major amputation in TAO patients did not seem to be related to the treatment methods despite a higher immediate patency rate observed after endovascular procedures. Additionally, we identified independent factors for major amputation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.